GlassScriptPhysician profile
Mahmood Solaiman
NPI 1316928849
$7,123.03
in general payments reported to CMS, 2019-2025
34 companies · $1,337 in 2025
The $1,337 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,234 · 2020: $435 · 2021: $745 · 2022: $1,217 · 2023: $1,131 · 2024: $1,024 · 2025: $1,337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,478 · Education: $13.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,478.31 |
| Education | $13.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,601.01 | 2019-2025 | Viberzi, Linzess, Creon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $507.46 | 2019-2024 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $498.90 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Celgene Corporation | $412.50 | 2021-2024 | Zeposia |
| Pfizer INC. | $386.00 | 2021-2025 | |
| Madrigal Pharmaceuticals | $346.72 | 2024-2025 | Rezdiffra |
| Gilead Sciences, INC. | $330.58 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $329.00 | 2019-2025 | Eohilia, Entyvio |
| Genzyme Corporation | $302.15 | 2022-2025 | |
| Ardelyx, INC. | $286.83 | 2022-2025 | Ibsrela |
| Allergan, INC. | $245.21 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $244.56 | 2022-2023 | Zeposia |
| Ironwood Pharmaceuticals, INC | $192.82 | 2019-2023 | Linzess |
| Shionogi INC | $171.97 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $154.68 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $153.55 | 2021-2022 | |
| Braintree Laboratories, INC. | $138.19 | 2019-2023 | Sutab, Suflave |
| Echosens North America, INC. | $127.89 | 2023 | Fibroscan |
| Regeneron Healthcare Solutions, INC. | $106.57 | 2022-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $97.77 | 2019-2022 | |
| Biofire Diagnostics, LLC | $84.96 | 2019 | |
| Alfasigma USA, INC. | $65.36 | 2022 | |
| Lilly USA, LLC | $59.97 | 2024 | Omvoh |
| Intercept Pharmaceuticals, INC. | $53.79 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $44.41 | 2023-2025 | Voquezna |
| Organon LLC | $26.98 | 2021-2024 | |
| Amgen INC. | $25.78 | 2023 | Avsola |
| Exact Sciences Corporation | $21.87 | 2025 | The Cologuard Plus Collection Kit |
| Ipsen Biopharmaceuticals, INC | $21.00 | 2024 | |
| Vivus LLC | $19.99 | 2024 | Pancreaze |
| Redhill Biopharma INC. | $18.71 | 2020 | |
| Alnylam Pharmaceuticals INC. | $18.55 | 2025 | Givlaari |
| Qol Medical, LLC | $14.02 | 2020 | |
| Celltrion USA INC. | $13.28 | 2024 | Zymfentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahmood Solaiman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.